NASDAQ:GDRX

GoodRx Competitors

$40.15
+0.69 (+1.75 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.10
Now: $40.15
$40.20
50-Day Range
$35.03
MA: $41.48
$54.03
52-Week Range
$33.39
Now: $40.15
$64.22
Volume1.14 million shs
Average Volume2.25 million shs
Market Capitalization$15.74 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

GoodRx (NASDAQ:GDRX) Vs. WDAY, BILI, VRSK, RNG, STNE, and ZEN

Should you be buying GDRX stock or one of its competitors? Companies in the industry of "data processing & preparation" are considered alternatives and competitors to GoodRx, including Workday (WDAY), Bilibili (BILI), Verisk Analytics (VRSK), RingCentral (RNG), StoneCo (STNE), and Zendesk (ZEN).

Workday (NASDAQ:WDAY) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Workday and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Workday$3.63 billion17.26$-480,670,000.00($1.42)-181.42
GoodRx$388.22 million40.55$66.05 millionN/AN/A

GoodRx has lower revenue, but higher earnings than Workday.

Insider and Institutional Ownership

68.0% of Workday shares are held by institutional investors. Comparatively, 43.4% of GoodRx shares are held by institutional investors. 26.5% of Workday shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Workday and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Workday-10.77%-10.56%-3.90%
GoodRxN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Workday and GoodRx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Workday191902.62
GoodRx16702.43

Workday presently has a consensus price target of $263.2222, indicating a potential upside of 2.18%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Workday.

Summary

GoodRx beats Workday on 6 of the 11 factors compared between the two stocks.

Bilibili (NASDAQ:BILI) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Bilibili and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bilibili$973.59 million38.24$-185,150,000.00($0.57)-185.61
GoodRx$388.22 million40.55$66.05 millionN/AN/A

GoodRx has lower revenue, but higher earnings than Bilibili.

Profitability

This table compares Bilibili and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bilibili-25.28%-30.90%-12.85%
GoodRxN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Bilibili and GoodRx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bilibili02902.82
GoodRx16702.43

Bilibili presently has a consensus price target of $66.0455, indicating a potential downside of 37.58%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Bilibili.

Insider and Institutional Ownership

39.1% of Bilibili shares are held by institutional investors. Comparatively, 43.4% of GoodRx shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GoodRx beats Bilibili on 7 of the 10 factors compared between the two stocks.

Verisk Analytics (NASDAQ:VRSK) and GoodRx (NASDAQ:GDRX) are both large-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Verisk Analytics and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verisk Analytics$2.61 billion11.38$449.90 million$4.3841.71
GoodRx$388.22 million40.55$66.05 millionN/AN/A

Verisk Analytics has higher revenue and earnings than GoodRx.

Profitability

This table compares Verisk Analytics and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verisk Analytics19.12%36.42%11.46%
GoodRxN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Verisk Analytics and GoodRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verisk Analytics04802.67
GoodRx16702.43

Verisk Analytics presently has a consensus price target of $195.4545, indicating a potential upside of 6.98%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than Verisk Analytics.

Insider & Institutional Ownership

88.2% of Verisk Analytics shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 2.6% of Verisk Analytics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Verisk Analytics beats GoodRx on 9 of the 11 factors compared between the two stocks.

RingCentral (NYSE:RNG) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares RingCentral and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RingCentral$902.86 million31.80$-53,610,000.00($0.19)-1,670.00
GoodRx$388.22 million40.55$66.05 millionN/AN/A

GoodRx has lower revenue, but higher earnings than RingCentral.

Profitability

This table compares RingCentral and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RingCentral-9.66%-12.62%-3.55%
GoodRxN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for RingCentral and GoodRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RingCentral002113.05
GoodRx16702.43

RingCentral presently has a consensus price target of $431.7727, indicating a potential upside of 36.08%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given RingCentral's stronger consensus rating and higher probable upside, research analysts clearly believe RingCentral is more favorable than GoodRx.

Insider & Institutional Ownership

86.3% of RingCentral shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 11.0% of RingCentral shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

RingCentral beats GoodRx on 7 of the 12 factors compared between the two stocks.

StoneCo (NASDAQ:STNE) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares StoneCo and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
StoneCo$626.01 million30.04$203.54 million$0.7096.87
GoodRx$388.22 million40.55$66.05 millionN/AN/A

StoneCo has higher revenue and earnings than GoodRx.

Profitability

This table compares StoneCo and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
StoneCo26.05%9.87%3.69%
GoodRxN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for StoneCo and GoodRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
StoneCo04702.64
GoodRx16702.43

StoneCo presently has a consensus price target of $66.20, indicating a potential downside of 2.37%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than StoneCo.

Insider & Institutional Ownership

61.5% of StoneCo shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

StoneCo beats GoodRx on 7 of the 9 factors compared between the two stocks.

Zendesk (NYSE:ZEN) and GoodRx (NASDAQ:GDRX) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings & Valuation

This table compares Zendesk and GoodRx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zendesk$816.42 million20.92$-169,650,000.00($1.19)-121.29
GoodRx$388.22 million40.55$66.05 millionN/AN/A

GoodRx has lower revenue, but higher earnings than Zendesk.

Profitability

This table compares Zendesk and GoodRx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zendesk-19.24%-22.55%-6.13%
GoodRxN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Zendesk and GoodRx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zendesk031202.80
GoodRx16702.43

Zendesk presently has a consensus price target of $143.00, indicating a potential downside of 0.93%. GoodRx has a consensus price target of $52.3571, indicating a potential upside of 30.40%. Given GoodRx's higher probable upside, analysts clearly believe GoodRx is more favorable than Zendesk.

Insider & Institutional Ownership

97.4% of Zendesk shares are owned by institutional investors. Comparatively, 43.4% of GoodRx shares are owned by institutional investors. 4.3% of Zendesk shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GoodRx beats Zendesk on 6 of the 11 factors compared between the two stocks.


GoodRx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Workday logo
WDAY
Workday
1.4$257.61+0.2%$62.60 billion$3.63 billion-137.76
Bilibili logo
BILI
Bilibili
1.3$105.80+3.2%$37.23 billion$973.59 million-97.96
Verisk Analytics logo
VRSK
Verisk Analytics
1.7$182.70+0.8%$29.66 billion$2.61 billion58.56Insider Selling
RingCentral logo
RNG
RingCentral
1.9$317.30+1.0%$28.71 billion$902.86 million-257.97
StoneCo logo
STNE
StoneCo
1.3$67.81+0.1%$18.81 billion$626.01 million111.16
Zendesk logo
ZEN
Zendesk
1.7$144.34+1.6%$17.08 billion$816.42 million-91.94
PagSeguro Digital logo
PAGS
PagSeguro Digital
1.5$47.92+0.6%$15.71 billion$1.39 billion57.73
Autohome logo
ATHM
Autohome
1.9$94.13+0.5%$11.87 billion$1.21 billion23.36
Five9 logo
FIVN
Five9
1.4$172.73+0.2%$11.58 billion$328.01 million-325.90
Zynga logo
ZNGA
Zynga
1.6$10.61+0.7%$11.49 billion$1.32 billion-353.67
Pegasystems logo
PEGA
Pegasystems
1.4$123.52+2.3%$9.99 billion$911.38 million-152.49
Globant logo
GLOB
Globant
1.4$221.02+0.1%$8.85 billion$659.33 million175.41
JOYY logo
YY
JOYY
2.5$100.01+3.3%$8.10 billion$3.67 billion7.58
DXC Technology logo
DXC
DXC Technology
1.6$31.44+0.1%$8.00 billion$19.58 billion-2.06
Proofpoint logo
PFPT
Proofpoint
1.4$131.33+0.2%$7.54 billion$888.19 million-47.76
Change Healthcare logo
CHNG
Change Healthcare
1.0$22.51+0.0%$6.90 billion$3.20 billion-40.93
Skillz logo
SKLZ
Skillz
1.8$17.26+0.1%$6.38 billionN/A0.00
Upwork logo
UPWK
Upwork
1.6$47.96+1.6%$5.99 billion$300.56 million-191.84
CoreLogic logo
CLGX
CoreLogic
1.9$79.79+0.1%$5.84 billion$1.76 billion27.42
Perspecta logo
PRSP
Perspecta
0.9$29.17+0.0%$4.70 billion$4.50 billion-6.51
Inovalon logo
INOV
Inovalon
1.2$29.95+0.0%$4.65 billion$642.41 million748.94
8X8 logo
EGHT
8X8
1.4$32.52+1.5%$3.50 billion$446.24 million-18.80
LiveRamp logo
RAMP
LiveRamp
1.9$51.09+3.7%$3.42 billion$380.57 million-39.00
Liberty TripAdvisor logo
LTRPB
Liberty TripAdvisor
0.0$45.21+0.5%$3.40 billion$1.56 billion-11.87
Shutterstock logo
SSTK
Shutterstock
1.7$92.90+0.3%$3.37 billion$650.52 million66.84Insider Selling
EVERTEC logo
EVTC
EVERTEC
1.7$39.56+0.3%$2.85 billion$487.37 million29.97
CarGurus logo
CARG
CarGurus
2.1$24.36+2.6%$2.85 billion$588.92 million42.00
Global Blue Group logo
GB
Global Blue Group
0.8$12.02+8.6%$2.17 billionN/A0.00
SciPlay logo
SCPL
SciPlay
1.4$17.00+2.2%$2.15 billion$465.80 million19.32
Yext logo
YEXT
Yext
1.6$15.10+0.1%$1.88 billion$298.83 million-13.60
CSG Systems International logo
CSGS
CSG Systems International
1.9$46.67+0.6%$1.54 billion$996.81 million22.22
trivago logo
TRVG
trivago
0.8$4.04+2.7%$1.43 billion$939.36 million-5.46
So-Young International logo
SY
So-Young International
1.1$9.59+0.3%$1.04 billion$165.42 million239.75
Cars.com logo
CARS
Cars.com
1.2$13.68+0.9%$922.24 million$606.68 million-1.11
Brightcove logo
BCOV
Brightcove
1.6$21.60+2.9%$869.36 million$184.46 million-58.38
Tucows logo
TCX
Tucows
0.6$81.52+1.5%$865.74 million$337.14 million92.64
Veritone logo
VERI
Veritone
1.0$24.43+3.6%$789.07 million$49.65 million-12.79
Sohu.com logo
SOHU
Sohu.com
1.4$18.90+12.0%$742.88 million$1.85 billion-5.03Gap Down
PCPL
CC Neuberger Principal Holdings I
2.2$10.98+2.7%$570.34 millionN/A0.00
Liberty TripAdvisor logo
LTRPA
Liberty TripAdvisor
1.0$6.05+1.7%$454.97 million$1.56 billion-1.59
ZIX logo
ZIXI
ZIX
1.9$7.57+1.2%$432.17 million$173.43 million-24.42
IBEX logo
IBEX
IBEX
1.4$22.70+3.9%$417.41 million$405.14 million27.02
Ooma logo
OOMA
Ooma
1.6$16.43+0.1%$372.96 million$151.59 million-82.15
NantHealth logo
NH
NantHealth
0.6$3.15+1.9%$350.66 million$95.96 million-7.16
GTY Technology logo
GTYH
GTY Technology
1.5$6.19+1.0%$341.26 million$36.44 million-8.84
Leaf Group logo
LEAF
Leaf Group
1.4$8.99+1.3%$321.85 million$154.96 million-20.43
SJ
Scienjoy
1.8$10.22+2.5%$312.79 millionN/A11.23Gap Up
BLCT
BlueCity
1.4$8.20+4.4%$292.34 million$107.18 million0.00
Castlight Health logo
CSLT
Castlight Health
0.7$1.76+4.0%$277.42 million$143.31 million-3.59
GSMG
Glory Star New Media Group
0.0$3.78+1.6%$218.81 millionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.